Search Results - "Rubin, J.L" :: K.UTB vyhledávací portál

Loading…

PUK24 USE OF BIOMARKERS IN PROPENSITY SCORE MATCHING TO MITIGATE CHANNELING BIAS IN A RETROSPECTIVE COHORT OF ESRD PATIENTS

by Wilson, S.M, Rubin, J.L
Published in Value in health (2011)

Get full text

Journal Article

Loading…

PUK15 a Managed Care Cost-Offset Model for Ferric Citrate, an Experimental Phosphate Binder That Can Reduce the Use of Erythropoiesis-Stimulating Agents and Intravenous Iron in Hemodialysis Patients with Hyperphosphatemia

by Mutell, R, Rubin, J.L, Bond, T.C, Mayne, T
Published in Value in health (01.06.2012)

Get full text

Journal Article

Loading…

PUK30 Once Monthly Erythropoiesis Stimulating Agent (ESA) Dosing May Reduce ESA Utilization Compared to Thrice-Weekly ESA Dosing

by Bond, T.C, Rubin, J.L, Wang, X, Yang, A
Published in Value in health (01.06.2012)

Get full text

Journal Article

Loading…

PUK32 Lower Case Mix Adjusters are Associated with Lower Erythropoiesis-Stimulating Agent (ESA) and Other Bundled Costs

by Sibbel, S.P, Rubin, J.L, Yang, A
Published in Value in health (01.06.2012)

Get full text

Journal Article

Loading…

PUK29 Erythropoietin-Stimulating Agent (ESA) Dose Recovery Following Hospitalization of End Stage Renal Disease (ESRD) Patients

by Wang, X, Bond, T.C, Rubin, J.L, Yang, A
Published in Value in health (01.06.2012)

Get full text

Journal Article

Loading…

PUK16 Reduced Use of Erythropoiesis-Stimulating Agents and Intravenous Iron with Use of the Phosphate Binder Ferric Citrate: a Facility-Level Cost-Offset Model Under the Medicare Bundle

by Mutell, R, Rubin, J.L, Bond, T.C, Mayne, T
Published in Value in health (01.06.2012)

Get full text

Journal Article

Loading…

DM1 IMPACT OF A PHARMACY REFILL MANAGEMENT SYSTEM ON OUTCOMES IN END STAGE RENAL DISEASE (ESRD) PATIENTS

by Rubin, J.L, Wilson, S.M, Golomb, J
Published in Value in health (2011)

Get full text

Journal Article

Loading…

PUK1 INCIDENCE AND 30-DAY MORTALITY OF COMMUNITY ACQUIRED PNEUMONIA (CAP) IN THE MEDICARE FEE-FOR-SERVICE (FFS) POPULATION

by Rubin, J.L, Li, S, Yu, H, Dunning, S, Sato, R
Published in Value in health (2011)

Get full text

Journal Article

Loading…

PRO13 LIMITATIONS OF COST-EFFECTIVENESS METHODS WHEN ANALYZING LIFE-EXTENDING TREATMENTS FOR RARE, CHRONIC, GENETIC DISEASES: A CYSTIC FIBROSIS CASE STUDY

by Lopez, A., Rubin, J.L., Chandler, C., Jena, A.B.
Published in Value in health (01.05.2019)

Get full text

Journal Article

Loading…

PMU46 Impact of Assumptions Used in Cost-Effectiveness Analysis (CEA) on the Outcomes of CEA across Disease Areas

by Holmes, H., Mahon, J., McGarry, L., Bromilow, T., Thorat, T., Wood, H., Rubin, J.L.
Published in Value in health (01.06.2021)

Get full text

Journal Article

Loading…

PRS31 Modelling Survival of People with Cystic Fibrosis (PWCF) Aged ≥12 YEARS Homozygous for the F508DEL Mutation Treated with Ivacaftor/Tezacaftor/Elexacaftor and Ivacaftor (IVA/TEZ/ELX)

by Vega-Hernandez, G., MacGregor, G., Lopez, A., Daly, C., Rubin, J.L.
Published in Value in health (01.06.2021)

Get full text

Journal Article

Loading…

PRS2 Modelling Survival of People with Cystic Fibrosis (PWCF) Aged ≥12 YEARS Heterozygous for the F508DEL Mutation with a Minimal Function Mutation Treated with Ivacaftor/Tezacaftor/Elexacaftor and Ivacaftor (IVA/TEZ/ELX)

by Vega-Hernandez, G., MacGregor, G., Lopez, A., Daly, C., Rubin, J.L.
Published in Value in health (01.06.2021)

Get full text

Journal Article

Loading…

191 Lung function and health care resource utilization in patients with cystic fibrosis

by Rubin-Cahill, J.L, Thayer, S, Watkins, A, Wagener, J, Hodgkins, P, Schechter, M.S
Published in Journal of cystic fibrosis (01.06.2015)

Get full text

Journal Article

Loading…

190 Frequency and costs of pulmonary exacerbations and association with % predicted FEV1 in patients with cystic fibrosis

by Rubin-Cahill, J.L, Thayer, S, Watkins, A, Wagener, J, Hodgkins, P, Schechter, M.S
Published in Journal of cystic fibrosis (01.06.2015)

Get full text

Journal Article

Loading…

MS1 VALIDATION OF MODELED 5-YEAR SURVIVAL OUTCOMES AMONG PATIENTS WITH CYSTIC FIBROSIS (CF) TREATED WITH THE CF TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATOR (CFTRM) IVACAFTOR USING US CF FOUNDATION PATIENT REGISTRY (USCFFPR) DATA

by Mcgarry, L., Lopez, A., Chandler, C., Pelligra, C., Alkhateeb, Z., Rubin, J.L., Liou, T.
Published in Value in health (01.05.2020)

Get full text

Journal Article

Loading…

PRO117 ACCESS TO ORPHAN DRUGS IN THE UNITED KINGDOM: A REVIEW OF NICE DECISIONS FROM 2017-2018

by Thorat, T., Sliman, R.C., Farinella, M., Vega, G., Jao, R., Kumar, J., Rubin, J.L.
Published in Value in health (01.11.2019)

Get full text

Journal Article

Loading…

PRO26 HEALTH CARE RESOURCE USE AND OUTCOMES AMONG INFANTS AND CHILDREN AGED <6 YEARS WITH CYSTIC FIBROSIS IN THE UNITED STATES

by Hassan, M., Thorat, T., Bonafede, M., Limone, B., McGarry, L., Rubin, J.L.
Published in Value in health (01.05.2019)

Get full text

Journal Article

Loading…

P067 Hospitalisations among children with cystic fibrosis aged <6 years

by Thorat, T., Hassan, M., Bonafede, M., Limone, B., McGarry, L., Rubin, J.L.
Published in Journal of cystic fibrosis (01.06.2019)

Get full text

Journal Article

Loading…

Atypical presentation of Henoch-Schonlein purpura: Case report and review of the literature

by Rubin, J.L., Moy, J.
Published in Journal of allergy and clinical immunology (01.02.2004)

Get full text

Journal Article

Loading…

190 Frequency and costs of pulmonary exacerbations and association with % predicted FEV 1 in patients with cystic fibrosis

by Rubin-Cahill, J.L., Thayer, S., Watkins, A., Wagener, J., Hodgkins, P., Schechter, M.S.
Published in Journal of cystic fibrosis (01.06.2015)

Get full text

Journal Article

Refine Results

Format

Subject Area

Topic

Language

Year of Publication

Database